Literature DB >> 9137493

Thymic carcinoma with autoimmune syndrome: successful treatment with weekly infusional high-dose 5-fluorouracil and leucovorin.

C H Hsu1, K H Yeh, A L Cheng.   

Abstract

Thymic carcinoma is known for its poor clinical outcome and unsatisfactory response to conventional chemotherapy. A 53-year-old woman was diagnosed as having metastatic thymic carcinoma in 1989. She received systemic chemotherapy containing cisplatin, doxorubicin, and cyclophosphamide, and involved-field radiotherapy. A durable complete remission was achieved and lasted for 4 years. When the disease recurred in 1995, she was found to have an autoimmune syndrome in addition to pleural effusion, a posterior mediastinal mass and a left adrenal mass. The autoimmune manifestations were seen as scleroderma, high titers of rheumatoid factor and anti-nuclear antibody. We adopted a novel HDFL regimen, which is composed of weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin, for this patient. Complete remission was achieved again, and autoimmune syndrome was well controlled.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9137493

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms.

Authors:  Kevin Wood; Elizabeth Byron; Linda Janisch; Ravi Salgia; Manish R Sharma
Journal:  Am J Clin Oncol       Date:  2018-10       Impact factor: 2.339

2.  Gemcitabine in patients previously treated with platinum-containing chemotherapy for refractory thymic carcinoma: radiographic assessment using the RECIST criteria and the ITMIG recommendations.

Authors:  Yusuke Okuma; Yukio Hosomi; Kageaki Watanabe; Satoshi Takahashi; Tatsuru Okamura; Tsunekazu Hishima
Journal:  Int J Clin Oncol       Date:  2015-12-08       Impact factor: 3.402

3.  Radiotherapy for invasive thymoma and thymic carcinoma. Clinicopathological review.

Authors:  R Mayer; C Beham-Schmid; R Groell; F M Smolle-Juettner; F Quehenberger; G F Stuecklschweiger; U Prettenhofer; H Stranzl; H Renner; A Hackl
Journal:  Strahlenther Onkol       Date:  1999-06       Impact factor: 4.033

4.  Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma.

Authors:  Yusuke Okuma; Yukio Hosomi; Shingo Miyamoto; Masahiko Shibuya; Tatsuru Okamura; Tsunekazu Hishima
Journal:  BMC Cancer       Date:  2016-02-25       Impact factor: 4.430

5.  SS-A52 antigen expression in thymic carcinoma accompanied with Sjögren syndrome: A case report.

Authors:  Tomomi Isono; Tomoko Wakasa; Hidenori Kusumoto; Keiji Shimada; Takafumi Ogawa; Hiroyuki Shiono
Journal:  Medicine (Baltimore)       Date:  2021-02-05       Impact factor: 1.817

6.  Clinical outcomes for patients with thymoma and thymic carcinoma after undergoing different front-line chemotherapy regimens.

Authors:  Wei-Li Ma; Chia-Chi Lin; Feng-Ming Hsu; Jang-Ming Lee; Jin-Shing Chen; Yen-Lin Huang; Yih-Leong Chang; Chin-Hao Chang; James Chih-Hsin Yang
Journal:  Cancer Med       Date:  2022-03-29       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.